These results indicate that concurrent inhibition of activin-class ligands and blockade of inflammatory processes by ActRIIA-Fc leads to persistent reversal of cardiopulmonary structural remodeling in severe experimental PAH, even in the apparent absence of actively circulating therapeutic molecules. The gene discussed is ACVR2A; the disease is pulmonary arterial hypertension.